Cargando…
Targeting CDK9 with selective inhibitors or degraders in tumor therapy: an overview of recent developments
As a catalytic subunit of the positive transcription elongation factor b (P-TEFb), cyclin-dependent kinase 9 (CDK9) has been demonstrated to contribute to carcinogenesis. This review focuses on the development of selective CDK9 inhibitors and proteolysis-targeting chimera (PROTAC) degraders. Twenty...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Taylor & Francis
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10243401/ https://www.ncbi.nlm.nih.gov/pubmed/37272701 http://dx.doi.org/10.1080/15384047.2023.2219470 |